| | |
| Clinical data | |
|---|---|
| Other names | 3-MPEA; meta-Methoxyphenethylamine; m-Methoxyphenethylamine; EA-1302; NSC-124706 |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.016.381 |
| Chemical and physical data | |
| Formula | C9H13NO |
| Molar mass | 151.209 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
3-Methoxyphenethylamine (3-MPEA) is a drug of the phenethylamine family. [1] [2] It is one of the methoxyphenethylamine positional isomers. [1] [2]
The drug showed very low affinity for the serotonin receptors in the rat stomach fundus strip (A2 = 1,290 nM). [1] [3] 3-MPEA is a low-potency partial agonist of the human trace amine-associated receptor 1 (TAAR1) (EC50 = 1,444 nM; Emax = 73%). [4] The effects of 3-MPEA in humans have not been reported and are unknown. [1]
3-MPEA was first described in the scientific literature by at least 1943. [5] [6] [1] It was studied at Edgewood Arsenal and received the code name EA-1302. [2] The drug was included as an entry in Alexander Shulgin's 2011 book The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds . [1]